ArticleAdvances in therapy2022

Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.

Ion Agirrezabal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.